Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lothar Bergmann

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Onkologie|February 19, 2010
[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma]Lothar Bergmann
Deutsche Medizinische Wochenschrift (1946)|April 1, 2016
[Systemic therapy of metastatic renal cell carcinoma]Luise Maute, Lothar Bergmann
Onkologie|February 19, 2010
[Outlook: Future therapy of renal cell carcinoma]Lothar Bergmann, Kurt Miller
Urologie (Heidelberg, Germany)|November 26, 2024
[Non-clear cell renal cell carcinoma]Marit Ahrens, Lothar Bergmann
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 22, 2010
Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell linesWolfgang Glienke, Eva Hausmann, Lothar Bergmann
Expert Review of Anticancer Therapy|December 10, 2013
Temsirolimus for advanced renal cell carcinomaLothar Bergmann, Luise Maute, Michael Guschmann
Deutsche Medizinische Wochenschrift (1946)|June 4, 2020
[What is new in the diagnosis and therapy of renal cell carcinoma?]Marit Ahrens, Arndt Hartmann, Lothar Bergmann
Expert Review of Anticancer Therapy|July 22, 2021
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overviewLothar Bergmann, Sarah Weber, Arndt Hartmann, et al.
Oncology Research and Treatment|February 26, 2019
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment OptionsMarit Ahrens, Sebastian Scheich, Arndt Hartmann, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 16, 2011
The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell linesWolfgang Glienke, Luise Maute, Johannes Wicht, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Onkologie|February 19, 2010
[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma]Lothar Bergmann
Deutsche Medizinische Wochenschrift (1946)|April 1, 2016
[Systemic therapy of metastatic renal cell carcinoma]Luise Maute, Lothar Bergmann
Onkologie|February 19, 2010
[Outlook: Future therapy of renal cell carcinoma]Lothar Bergmann, Kurt Miller
Urologie (Heidelberg, Germany)|November 26, 2024
[Non-clear cell renal cell carcinoma]Marit Ahrens, Lothar Bergmann
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 22, 2010
Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell linesWolfgang Glienke, Eva Hausmann, Lothar Bergmann
Expert Review of Anticancer Therapy|December 10, 2013
Temsirolimus for advanced renal cell carcinomaLothar Bergmann, Luise Maute, Michael Guschmann
Deutsche Medizinische Wochenschrift (1946)|June 4, 2020
[What is new in the diagnosis and therapy of renal cell carcinoma?]Marit Ahrens, Arndt Hartmann, Lothar Bergmann
Expert Review of Anticancer Therapy|July 22, 2021
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overviewLothar Bergmann, Sarah Weber, Arndt Hartmann, et al.
Oncology Research and Treatment|February 26, 2019
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment OptionsMarit Ahrens, Sebastian Scheich, Arndt Hartmann, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 16, 2011
The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell linesWolfgang Glienke, Luise Maute, Johannes Wicht, et al.
Pageof 5